Who's Actually Winning Healthtech Right Now (and Who's Still Being Left Behind)

‍The Regenerative Founder

The healthtech market in 2026 looks different from what the pitch decks promised five years ago. The winners aren't always the ones with the biggest teams or the flashiest consumer brands. They're lean teams solving unglamorous problems, operators who figured out how to rent infrastructure instead of building it, and a new generation of clinicians swapping quick fixes for treatments that help the body repair itself. Underneath all of that is a harder truth. The progress is uneven, and women's health is still being left behind.

Here's how the market is being won, and where the next opening is.

Small teams, outsized leverage

The money is flowing to AI. In the first half of 2025, AI-enabled healthcare startups took 62% of all U.S. digital health venture funding, and their average round came in at an 83% premium over non-AI peers [1].

But what these companies are building is more interesting than the headline figure. Many of the fastest-growing companies are tiny teams automating the back office that healthcare has neglected for decades. Take LunaBill, a Y Combinator company building AI voice agents for medical billing. Insurance follow-up calls make up the bulk of a billing team's day, and each one averages about half an hour. Since launching, the company has signed $764K in contracted ARR and converted every pilot into a paying customer [2]. That's a two-founder story. Another YC company, Elite, runs the front office for practices, handling scheduling, triage, refills and intake inside the practice's existing EHR. It goes live in days and charges per resolved patient interaction [3].

The pattern is clear. Small teams win by picking one painful workflow, embedding into systems practices already use, and pricing on outcomes rather than seats. They don't ask hospitals to rip anything out.

There is a warning, though. The giants have arrived. Microsoft launched Copilot Health in March 2026, and OpenAI bought the interoperability startup Torch Health for roughly $100 million in January before launching ChatGPT Health [1]. If your product is a thin layer over a general model, you're competing with companies that have unlimited distribution. The defensible position for a small team is depth: specialty-specific knowledge, deep integrations, and proof that you move a number a CFO cares about.

The outsourced MRI economy

The full-body scan market may be the clearest example of a new business model in healthcare: sell the experience and the insight, and rent the heavy machinery.

Neko Health currently leads full-body scanning overall, Prenuvo is the leader in dedicated whole-body MRI, and Function Health through Ezra is its strongest challenger. Neko owns its hardware. By contrast, most MRI competitors rely at least partly on equipment and infrastructure that hospitals or radiology chains already have. That asset-light approach is what let the category scale so fast. Prenuvo has passed 170,000 completed scans, and Neko has passed 100,000 [4].

Price has become the battleground. Function Health acquired Ezra in May 2025 and launched a $499 full-body MRI scan [5], and Ezra's Flash AI can complete that entry scan in as little as 22 minutes [6]. Compare that with Prenuvo at $2,499, and note that none of these providers bill insurance [7].

The lesson for founders is that AI shortens scan time, shorter scans lower costs, and lower costs expand the market. This is a real playbook.

Founders should also be honest about where it falls short. Both Ezra and Prenuvo face criticism over high false-positive rates, and major medical societies do not endorse whole-body MRI as routine preventive screening [6]. In January 2026, The Washington Post reported a lawsuit alleging a Prenuvo scan missed signs of a catastrophic stroke [8]. Consumer demand is real. Clinical consensus hasn't caught up. The companies that last will be the ones that build evidence, not just awareness.

From fillers to regeneration

The aesthetics sector is going through its own quiet revolution, and it fits the regenerative thesis well.

The overfilled, identical "Instagram face" is out. That look has declined sharply, and polynucleotides, injectable biostimulators made from filtered DNA fractions, have become one of the standout treatments of 2026. Rather than adding artificial volume, they signal the body's own cells to produce collagen and elastin [9]. Clinicians describe the change as clinical as well as cosmetic: the field is moving toward diagnostic thinking, assessing what's happening in the tissues at a biological level rather than judging faces from the outside [10].

Patients are leading the charge ahead of their own understanding. In NewBeauty's summer 2026 survey, only 37% of respondents said they were familiar with regenerative treatments, yet 71.2% would consider PRP injections and just over half would consider exosomes [11].

That gap between curiosity and knowledge is both the opportunity and the risk. Two systematic reviews from early 2026 found positive associations between polynucleotides and skin elasticity, hydration and wrinkle depth, though both called for larger trials. Meanwhile, no exosome product has FDA approval for aesthetic use [12]. For founders in this space, whether you're building clinic software, a product line, or a practice brand, the moat is credibility. The operators who say plainly what's proven and what's still emerging will outlast the ones riding the hype.

Where medicine is genuinely improving: surgery and cancer

Behind the consumer noise, the hard clinical science is moving too, especially in surgery and oncology.

Robotic surgery is finally producing randomized evidence rather than just feasibility studies. In the REAL trial, robotic surgery improved three-year locoregional control, disease-free survival, and early functional recovery compared with laparoscopy for middle and low rectal cancer, although overall survival did not differ [13]. The robots are also becoming data platforms. The da Vinci 5 adds advanced sensing, imaging and data-capture capabilities that make it far more suitable for developing AI models [14]. Every operation becomes training data, and that compounds.

Cancer detection saw its most important evidence of the decade this year. GRAIL's NHS-Galleri trial, the first and only randomized controlled trial of a multi-cancer early detection test, followed more than 142,000 participants aged 50 to 77 over three years [15]. The results were mixed but meaningful. It missed its primary endpoint of reducing combined Stage III and IV cancers, but it cut Stage IV diagnoses of 12 aggressive cancers by 22% and 26% in the second and third screening rounds, quadrupled cancer detection when added to standard screening, and increased Stage I and II screen-detected cancers by 128%. An FDA advisory committee is set to review Galleri's approval application this fall [16].

If you're building in surgical or oncology tooling, the bar has been raised. Randomized data is now the currency.

The gap no one has closed: women's health

This is where the story breaks down.

All of the progress above is real, but it doesn't reach everyone equally. The World Economic Forum describes women's health as a $1 trillion opportunity, yet it captures only 6% of private healthcare investment [17]. Most of that small share is narrowly concentrated, too: about 90% of it goes to women's cancers, reproductive health and maternal health [18]. Cancer care improvements do reach women. But almost everything else in a woman's health, including heart disease, autoimmune conditions, menopause, and pain, is still underfunded and under-researched.

The numbers are moving the wrong way in places. Deloitte found women's health investment in health-tech fell 56% in 2025, from nearly $1.2 billion to $478 million, even as overall health-tech funding rose to $28.6 billion [18]. When records are broken, they're often skewed; discussing recent record totals, one foundation president pointed out that half of it went to just two companies [19].

The clinical reality is stark. Endometriosis takes 7 to 10 years to diagnose, PCOS affects one in ten women, and menopause support remains inadequate despite affecting half the population [20]. McKinsey adds a figure that should change how investors see the market: 43% of the female health burden comes from conditions that don't affect women uniquely or disproportionately, which means standard women's health investment frameworks don't even track them [19].

Founders also face structural friction that has nothing to do with product quality. Men's health companies could advertise freely from day one and reach the exponential growth curves later-stage investors want, while women's health companies with equivalent teams and markets have been held to linear growth [21].

What this means if you're building

Put it all together and the map looks like this. Small teams are winning with narrow, workflow-deep AI products that pay for themselves. Asset-light models are proving you don't need to own the scanner to own the customer. Aesthetics is maturing from volume to biology, and credibility is becoming the differentiator. Surgery and oncology are generating the kind of randomized evidence that turns innovation into standard care.

The biggest unclaimed opportunity sits where all of those lessons meet. Women's health needs the same lean-team discipline, the same AI-driven diagnostics, and the same evidence-first approach that is transforming cancer and surgery. The capital isn't there yet, and neither is the data. For a founder, that's the gap worth building into, because markets that are this underserved don't stay that way forever.

The founders who close it won't just build good businesses. They'll help medicine finally see half its patients clearly.

Bibliography

All online sources accessed 22 September 2026.

1. Latent. "AI in Healthcare Product Development: What Healthtech Teams Are Actually Building in 2026." 8 August 2026. Citing Rock Health, H1 2025 Digital Health Funding Report. https://www.latenthq.com/insights/ai-in-healthcare-product-development-2026
2. Y Combinator. "Health Tech Startups Funded by Y Combinator (2026)" (LunaBill company profile). https://www.ycombinator.com/companies/industry/health-tech
3. Y Combinator. "Healthcare Startups Funded by Y Combinator (2026)" (Elite company profile). https://www.ycombinator.com/companies/industry/healthcare
4. New Market Pitch. "Full-Body Scans: Which Startup Is Ahead?" 20 July 2026. https://newmarketpitch.com/blogs/news/longevity-full-body-scans-startup
5. Capoot, Ashley. "Function Health Buys Ezra, Launches Full-Body Scan for a Third of the Price." CNBC, 5 May 2025. https://www.cnbc.com/2025/05/05/function-health-mri-ezra.html
6. Lifespan Vault. "Ezra Full Body MRI Review 2026." Verified 19 June 2026. https://lifespanvault.com/ultra-premium/ezra-mri
7. Vitality Scout. "Full Body MRI Scan Cost (2026)." 25 June 2026. https://vitalityscout.com/guides/full-body-mri-scan-cost
8. Travel Anywhere. "Full-Body MRI Travel 2026: Prenuvo vs Ezra vs International." 6 May 2026 (summarising The Washington Post's January 2026 reporting). https://www.travelanywhere.blog/blog/full-body-mri-travel-2026-prenuvo-ezra-international-comparison
9. Save Face. "Aesthetic Trends 2026: The Rise of Regenerative Medicine & Safety." 17 July 2026. https://www.saveface.co.uk/en/blog/post/aesthetic-trends-2026-the-rise-of-regenerative-medicine-safety
10. The Aesthetic Guide. "Regenerative Medicine's Polarizing Shift in Aesthetics." 30 March 2026. https://www.theaestheticguide.com/health-wellness/regenerative-aesthetics-2026-regenerative-medicine-s-polarizing-shift-in-aesthetics
11. NewBeauty. "New Report Shows Regenerative Aesthetics Is More Than a Buzzword" (State of Aesthetics Summer 2026). https://www.newbeauty.com/view/regenerative-aesthetics-state-of-aesthetics-2026
12. IAPAM. "Regenerative Aesthetics 2026: What the Evidence Actually Supports." 26 May 2026. https://iapam.com/regenerative-aesthetics-2026-evidence-guide
13. Kagawa, Hiroyasu, and Yusuke Kinugasa. "Essential Updates 2024–2026: Advances in Colorectal Cancer Surgery." Annals of Gastroenterological Surgery, 1 August 2026. doi:10.1002/ags3.70260
14. Katsimperis, Stamatios, et al. "Advancing Genitourinary Cancer Surgery: The Role of Artificial Intelligence and Robotics." Journal of Clinical Medicine 15, no. 10 (2026): 3856. doi:10.3390/jcm15103856
15. GRAIL, Inc. "Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses..." Press release, 19 February 2026. https://investors.grail.com/news-releases/news-release-details/landmark-nhs-galleri-trial-demonstrates-substantial-reduction
16. GRAIL, Inc. Second-quarter 2026 business update, 5 August 2026. https://grail.com/?p=28076
17. World Economic Forum. "IWD26: Leaders on Women's Health Research and Funding Bias." 8 March 2026. https://www.weforum.org/stories/2026/03/international-womens-day-2026-womens-health-research-funding/
18. Mean CEO. "Femtech Startup Funding Statistics." September 2026 (citing WEF/BCG, January 2026; SVB; and Deloitte). https://blog.mean.ceo/femtech-startup-funding-statistics/
19. Stengel, Geri. "Women's Health Is Breaking Records and Breaking No Ceilings." Forbes, 3 April 2026 (citing McKinsey Health Institute, Closing the Women's Health Gap). https://www.forbes.com/sites/geristengel/2026/04/03/womens-health-is-breaking-records-and-breaking-no-ceilings/
20. Capital Cell. "Why Now Is the Time to Invest in Women's Health Innovation." 13 February 2026. https://capitalcell.com/en/femtech-in-europe/
21. BeautyMatter. "Femtech Funding Gap: How Bias in Banking and Tech Is Holding Back Women's Health." 19 May 2026. https://beautymatter.com/articles/financial-system-womens-health

‍